Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAG + Venetoclax vs CLAG in Relapsed/Refractory AML
NCT06763666Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Feb 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Composite Complete Remission at 28 days. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06763666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06763666.